MRM Health logo
Startup

MRM Health

See MRM Health's full profile

BOOK A DEMO
Headquarters

Belgium

Founded Year

2020

Total Funding

$15.8M

Employees

11 - 50

Status

Active


About MRM Health

MRM Health is a biopharmaceutical company focused on the discovery and development of innovative therapeutics based on the human microbiome.

Headquarters

Belgium


General Information on MRM Health

Brand name MRM Health
Company name MRM Health N.V
Website https://mrmhealth.com/
Founded year 2020
Employees 11 - 50
Founding team

Sam Possemiers

Contact [email protected]
+3292411188

Find startup solutions in your specific business context

The INNOSPOT Startup Discovery platform helps you to find the right startup solutions by leveraging the world's most powerful Startup Search Engine analyzing millions of data points.
BOOK A DEMO

Recent News and Activity about MRM Health

企业新闻联播 (Corp123) 07.06.2022
MRM Health Reports Preclinical Results Showing a 9-Strain Ba

企业新闻联播(corp123.cn)讯: MRM Health Reports Preclinical Results Showing a 9-Strain Bacterial Consortium Delays Non-Alcoholic Fatty Liver Disease Progression and Liver Fibrosis GHENT, Belgium, June 07, 2022 (GLOBE NEWSWIRE) --MRM Health, a clinical-stage biopharmaceutical company developing next-generation live microbiome consortia therapeutics, announces the publication of preclinical research relating to its ongoing program in non-alcoholic fatty ...

中文商业新闻网 (Chinese business news network) 07.06.2022
MRM Health Reports Preclinical Results Showing a 9-Strain Bacterial Consortium Delays Non-Alcoholic Fatty Liver Disease Progression and Liver Fibrosis

MRM Health Reports Preclinical Results Showing a 9- Strain Bacterial Consortium Delays Non-Alcoholic Fatty Liver Disease Progression and Liver Fibrosis

Vlaamse Federatie van Beleggers 07.06.2022
ACKERMANS & VAN HAAREN - MRM Health Reports Preclinical Results Showing a 9-Strain Bacterial Consortium Delays Non-Alcoholic Fatty Liver Disease Progression and Liver Fibrosis (07.06.2022)

07 juni 2022 Ackermans & van Haaren Bijlagen ACKVH - mrm-hea... Deel dit artikel

VIB 07.06.2022
spin-off MRM Health reports positive preclinical results in non-alcoholic fatty liver disease

MRM Health is a VIB spin-off founded in 2020 by Sam Possemiers in a joint venture with VIB. Using a 9-strain bacterial consortium, MRM Health’s laboratories led by Dr. Salvador Augustin and Dr. Maria Martell of the University Hospital of Vall d’Hebron were able to slow down disease progression in Non-Alcoholic Fatty Liver Disease (NAFLD). Preclinical results show that a live bacterial consortium of 9 rationally selected gut commensal strains ...

MRM Health news
Finanzen.ch 07.06.2022
MRM Health NV : MRM Health Reports Preclinical Results Showing a 9-Strain Bacterial Consortium Delays Non-Alcoholic Fatty Liver Disease Progression and Liver Fibrosis

Weiter zum vollständigen Artikel bei "Investegate" BITCOIN KURSZIEL 100'000 US-DOLLAR? WELCHER COIN KÖNNTE DER NÄCHSTE VERDOPPLER SEIN? Informieren Sie sich aus erster Hand über Nachrichten, die Krypto-Kurse bewegen. Abonnieren Sie jetzt kostenlos unseren neuen Krypto-Newsletter! Analysen zu MRM Alle Kaufen Hold Verkaufen Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und ...

中文商业新闻网 (Chinese business news network) 08.12.2021
MRM Health Announces First Patient Dosed with Next Generation Live Microbiome Consortia Therapeutic MH002 in Phase 1b/2a Study in Patients with Ulcerative Colitis

MRM Health Announces First Patient Dosed with Next Generation Live Microbiome Consortia Therapeutic MH002 in Phase 1 b/2a Study in Patients with Ulcerative Colitis

中文商业新闻网 (Chinese business news network) 28.09.2021
MRM Health Receives CTA Approval for Phase 1b/2a Trial with Next Generation Optimized Consortium Therapeutic MH002 in Ulcerative Colitis

GHENT, Belgium, Sept. 28, 2021 (GLOBE NEWSWIRE) -- MRM Health, a biopharmaceutical company developing next-generation live microbiome consortia therapeutics, announced today that they have received regulatory approval from the Federal Agency for Medicines and Health Products (FAMHP) in Belgium to start a Phase 1b/2a trial with the novel next-generation optimized consortium therapy, MH002, in patients with mild-to-moderate ulcerative colitis ...

Finanzen.ch 28.09.2021
MRM Health NV : MRM Health Receives CTA Approval for Phase 1b/2a Trial with Next Generation Optimized Consortium Therapeutic MH002 in Ulcerative Colitis

Weiter zum vollständigen Artikel bei "Investegate" Analysen zu CTA Holding Alle Kaufen Hold Verkaufen

VIB 28.09.2021
VIB spin-off MRM Health Receives CTA Approval for Phase 1b/2a Trial

MH002 is the first rationally-designed consortium therapy, in which key disease-driving mechanisms guide therapeutic microbial strain selection, to enter clinical studies in patients. Developed through MRM Health’s proprietary Microbiome Optimization Technology, MH002 consists of 6 well-characterized commensal strains that are optimized to form a synergistic micro-ecosystem driving differentiated potency, resiliency, and engraftment. Combining ...